{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:08:04Z","timestamp":1786640884331,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the success of long-term antiretroviral therapy (ART), immune dysfunction\u2014including incomplete T helper cell recovery, immune activation, and inflammation\u2014persists and may affect the benefits of analytical ART treatment interruption (ATI) trials among people living with human immunodeficiency virus (HIV) (PLHIV) in sub-Saharan Africa (SSA). This narrative review summarizes evidence of incomplete immune function recovery among PLHIV on long-term ART and potential interventions to enhance their ability to participate in ATI trials with immunotherapies in the quest for an HIV cure in SSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A PubMed search query was used \u201c([Immunity, Innate{MeSH Terms}] OR [Adaptive Immunity{MeSH Terms}] AND [HIV{MeSH Terms}] AND [Anti-HIV Agents{MeSH Terms}] AND [function{Title\/Abstract} OR dysfunction{Title\/Abstract} OR recovery{Title\/Abstract} OR restoration{Title\/Abstract} OR reconstitution{Title\/Abstract} OR regeneration{Title\/Abstract}])\u201d, which retrieved 165 articles. These articles were filtered using an English-language filter, resulting in 160 papers. This query was translated to Web of Science and Google Scholar. In addition, we conducted a specific literature search on documented \u201ccured\u201d HIV cases globally to understand innate and adaptive immune functions relevant to supporting post-ART immunological viral control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Persistent dysfunction of host innate and adaptive immunity during suppressive ART is reported in SSA HIV treatment cohorts. Natural killer (NK) cells, dendritic cells, and monocyte dysfunction potentially limit post-ART viral control. In addition, persistently impaired CD4 and CD8 T-cell proliferation capacity, immune activation, and exhaustion during ART may limit host HIV-specific responses during ATI trials with broadly neutralizing antibodies (bNAbs) and therapeutic vaccines, thereby increasing the risk of post-ART viral rebound. Similarly, adjunct therapies with TLR7 agonists, such as vesatolimod, could potentially increase cytotoxic capabilities of dendritic and natural killer cells to improve HIV latency reversal and viral clearance during ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Innovative combination immunotherapies to avert persistent immune dysfunction, such as therapeutic vaccines, combination bNabs, enhancer of zeste homolog 2 (EZH2) inhibitors to boost CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell function and augment post-ART viral control, and latency reversal agents to increase cytotoxicity potential of dendritic cell and natural killer cells, among others, could potentially optimize HIV-specific CD8 T-cell cytotoxicity and viral clearance, and delay viral rebound during ATI trials in SSA.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1754996","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:41:06Z","timestamp":1774593666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa"],"prefix":"10.3389","volume":"17","author":[{"given":"Patricia","family":"Kankundiye","sequence":"first","affiliation":[{"name":"Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Infectious Diseases Institute, Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Africa-Europe Cluster of Excellence in Translational Science in Infection, Immunity and Inflammation (CoRE Triii), Makerere University College of Health Sciences","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praiscillia","family":"Kia","sequence":"additional","affiliation":[{"name":"Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Infectious Diseases Institute, Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Africa-Europe Cluster of Excellence in Translational Science in Infection, Immunity and Inflammation (CoRE Triii), Makerere University College of Health Sciences","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kankaka","sequence":"additional","affiliation":[{"name":"Africa-Europe Cluster of Excellence in Translational Science in Infection, Immunity and Inflammation (CoRE Triii), Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Research Department, Rakai Health Sciences Project","place":["Kalisizo, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Nabatanzi","sequence":"additional","affiliation":[{"name":"Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Infectious Diseases Institute, Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Africa-Europe Cluster of Excellence in Translational Science in Infection, Immunity and Inflammation (CoRE Triii), Makerere University College of Health Sciences","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokameh","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Africa-Europe Cluster of Excellence in Translational Science in Infection, Immunity and Inflammation (CoRE Triii), Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Department of Pathology, Erasmus Medical Centre","place":["Rotterdam, Netherlands"]},{"name":"Department of Urology, Erasmus Medical Centre","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damalie","family":"Nakanjako","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Africa-Europe Cluster of Excellence in Translational Science in Infection, Immunity and Inflammation (CoRE Triii), Makerere University College of Health Sciences","place":["Kampala, Uganda"]},{"name":"Department of Medicine, School of Medicine, Makerere University College of Health Sciences","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30086-3","article-title":"Improved life expectancy of people living with HIV: who is left behind","volume":"4","author":"Katz","year":"2017","journal-title":"Lancet HIV"},{"key":"B2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/COH.0000000000000298","article-title":"Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population","volume":"11","author":"Wandeler","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1236460","article-title":"Recent advances in poor HIV immune reconstitution: what will the future look like?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Microbiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S356771","article-title":"CD56(dim) NK cell is an important factor in T cell depletion of cART-treated AIDS patients","volume":"15","author":"Qian","year":"2022","journal-title":"Int J Gen Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12981-018-0194-y","article-title":"Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells","volume":"15","author":"Nabatanzi","year":"2018","journal-title":"AIDS Res Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167640","article-title":"Increased natural killer cell activation in HIV-infected immunologic non-responders correlates with CD4+ T cell recovery after antiretroviral therapy and viral suppression","volume":"12","author":"Luo","year":"2017","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.08.014","article-title":"NK cells of HIV-1-infected patients with poor CD4(+) T-cell reconstitution despite suppressive HAART show reduced IFN-\u03b3 production and high frequency of autoreactive CD56(bright) cells","volume":"190","author":"Giuliani","year":"2017","journal-title":"Immunol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00272","article-title":"Perturbations of Monocyte\u00a0Subsets and Their Association with T Helper Cell Differentiation in Acute and Chronic HIV-1-Infected Patients","volume":"8","author":"Chen","year":"2017","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121019","article-title":"Persistence of pathological distribution of NK cells in HIV-infected patients with\u00a0prolonged use of HAART and a sustained immune response","volume":"10","author":"Frias","year":"2015","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2172-15-2","article-title":"High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort","volume":"15","author":"Bayigga","year":"2014","journal-title":"BMC Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000362","article-title":"Programmed death-1 expression on HIV-1-specific CD8+ T cells is shaped by epitope specificity, T-cell receptor clonotype usage and antigen load","volume":"28","author":"Kl\u00f8verpris","year":"2014","journal-title":"AIDS"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04526.x","article-title":"Impaired phagocytosis among patients infected by the human immunodeficiency virus: implication for a role of highly active anti-retroviral therapy","volume":"167","author":"Michailidis","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2336091100","article-title":"Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates","volume":"100","author":"Mavilio","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409872102","article-title":"Characterization of CD56-\/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals","volume":"102","author":"Mavilio","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.3390\/diagnostics12112676","article-title":"Immunological interactions between intestinal helminth infections and tuberculosis","volume":"12","author":"Bhengu","year":"2022","journal-title":"Diagnostics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-3024.2006.00901.x","article-title":"Co-infection of helminths and malaria: modulation of the immune responses to malaria","volume":"28","author":"Hartgers","year":"2006","journal-title":"Parasite Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41577-021-00649-1","article-title":"Engaging innate immunity in HIV-1 cure strategies","volume":"22","author":"Board","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01741-5","article-title":"Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells","volume":"25","author":"Board","year":"2024","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1026070","article-title":"Alterations in circulating markers in HIV\/AIDS patients with poor immune reconstitution: Novel insights from microbial translocation and innate immunity","volume":"13","author":"Xiao","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105559","article-title":"Na\u00efve B cells with low differentiation improve the immune reconstitution of HIV-infected patients","volume":"25","author":"Jia","year":"2022","journal-title":"iScience"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-14-26","article-title":"Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort","volume":"14","author":"Nakanjako","year":"2013","journal-title":"BMC Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-43","article-title":"High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort","volume":"11","author":"Nakanjako","year":"2011","journal-title":"BMC Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2012.02.006","article-title":"The influence of HIV on CD127 expression and its potential implications for IL-7 therapy","volume":"24","author":"Crawley","year":"2012","journal-title":"Semin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152951","article-title":"Cellular and molecular insights into incomplete immune recovery in HIV\/AIDS patients","volume":"14","author":"Yan L","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41586-025-09932-w","article-title":"CD8+ T cell stemness precedes post-intervention control of HIV viraemia","volume":"650","author":"Kiani","year":"2026","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41586-025-09929-5","article-title":"Combination immunotherapy induces post-intervention control of HIV","volume":"650","author":"Peluso","year":"2026","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"115652","DOI":"10.1016\/j.celrep.2025.115652","article-title":"EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes","volume":"44","author":"Gramatica","year":"2025","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s43856-025-01266-y","article-title":"Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1","volume":"6","author":"Bail\u00f3n","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1038\/s41467-022-34171-2","article-title":"Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity","volume":"13","author":"Ros\u00e1s-Umbert","year":"2022","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3071","article-title":"The TLR7 agonist\u00a0vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy","volume":"13","author":"SenGupta","year":"2021","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09929-5","article-title":"Correlates of HIV-1 control after combination immunotherapy","volume":"650","author":"Peluso","year":"2026","journal-title":"Nature"},{"key":"B34","volume-title":"UNAIDS DATA 2023","year":"2023"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.smim.2021.101471","article-title":"Residual immune dysfunction under antiretroviral therapy","volume":"51","author":"Cai","year":"2021","journal-title":"Semin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.127113","article-title":"Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression","volume":"4","author":"Lisco","year":"2019","journal-title":"JCI Insight"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.029","article-title":"SnapShot: natural killer cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12442","article-title":"Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial","volume":"20","author":"Nakanjako","year":"2015","journal-title":"Trop Med Int Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2400870","article-title":"Pitavastatin and cardiovascular disease in HIV","volume":"389","author":"Grinspoon","year":"2023","journal-title":"Reply. N Engl J Med"},{"key":"B42","first-page":"83","article-title":"Update on HIV-1 diversity in africa: A decade in review","volume":"14","author":"Lihana","year":"2012","journal-title":"AIDS Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v15030789","article-title":"Opportunities for CAR-T cell immunotherapy in HIV cure","volume":"15","author":"Campos-Gonzalez","year":"2023","journal-title":"Viruses"},{"key":"B44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"Lancet HIV"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1576667","article-title":"HIV cure research contributions from Africa in the last three decades","volume":"16","author":"Nakanjako","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1754996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:41:09Z","timestamp":1774593669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1754996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2026.1754996"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1754996","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1754996"}}